Berry Genomics and Ajlan & Bros Holding Subsidiaries Establish a Joint Venture to Support ‘Vision 2030’
BEIJING, March 27, 2023 /PRNewswire/ -- Xcelom Limited, a subsidiary of Berry Genomics, has recently signed a cooperation agreement with Ajlan & Bros Medical Company, an Ajlan & Bros Holding subsidiary, to establish a joint venture that will support Saudi Arabia's "Vision 2030." The joint venture will focus on genetic testing in the field of reproductive health and carry...
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies
Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform - BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative...
PharmaBlock Opens New R&D Facility in Pennsylvania — Expanding Capacity to Deliver GMP Projects
WEST CHESTER, Pa., March 27, 2023 /PRNewswire/ -- PharmaBlock (stock code: 300725.SZSE), a global, fully integrated CDMO company focused on innovative chemistry and low-carbon manufacturing, announces the opening of its new R&D facility in West Chester, Pennsylvania. The facility expands the company's footprint in the US and enables more efficient process R&D services and fast delivery of clinical-stage GMP projects to global partners....
YS Biopharma’s PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical significance (95%CI: 2.1, 3.4, P<0.0001) based on interim data analysis The trial also met its key secondary endpoint of superior...
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
SHANGHAI, March 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines in Greater China and other parts of Asia, announced today that it has received full upfront payment of $280 million from Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., for the transaction around Trodelvy®...
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older Joenja® is expected to launch in the US in early April Pharming will host a conference call for investors...
‘Generations Connect’ Project aims to help boost the well-being of 10,000 elderly
HKU medical students to participate in community visits to encourage eHealth literacy improvement of the elderly HONG KONG, March 24, 2023 /PRNewswire/ -- e-Health Literacy is closely related to the health and well-being of the elderly. Sino Group and the Ng Teng Fong Charitable Foundation, in collaboration with the School of Nursing, LKS Faculty of Medicine of the University of...
Orion Health strengthens North American operations with new technology and leadership
Amadeus Unified Healthcare Platform set to change healthcare in North America AUCKLAND, New Zealand, March 24, 2023 /PRNewswire/ -- Orion Health, a global leader in population health software, is strengthening its position in North America with new technology and the appointment of James Rice as Executive Vice President for North America. With operations in 12 U.S States and seven...
ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting
WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-directed exatecan-based antibody-drug conjugate (ADC) with a novel hydrophilic linker, at the American Association for Cancer Research (AACR) Annual...
CGTN: How China continues optimizing its COVID-19 response amid other outbreaks
BEIJING, March 24, 2023 /PRNewswire/ -- China has entered a new phase of epidemic prevention and control after it downgraded the management of COVID-19 response into Class B infectious diseases. "The overall situation of epidemic response is good nationwide," according to a meeting held by the Standing Committee of the Political Bureau of the Communist Party of China Central...
